Heidi Braun
Internal Medicine · Pooler, GANPI 1508943309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $825 and has fallen 71.3% since, to $237 in 2025.
Across 124 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$582
- Axsome Therapeutics, Inc.$572
- Novo Nordisk$294
- Lilly USA, LLC$219
- GSK$192
- AbbVie$188
- plus $964 from 16 others
What the payments were for
- Food & beverage$3,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $582 |
| Axsome Therapeutics, Inc. | 16 | $572 |
| Novo Nordisk | 15 | $294 |
| Lilly USA, LLC | 14 | $219 |
| GSK | 6 | $192 |
| AbbVie(2 entities) | 5 | $188 |
| Vanda Pharmaceuticals Inc. | 8 | $160 |
| AstraZeneca | 8 | $140 |
| Dexcom, Inc. | 1 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 2 | $93 |
| Pfizer | 4 | $73 |
| Novartis | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Lundbeck LLC | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$287
- Repatha$245
- VIBERZI$132
- RYBELSUS$105
- DEXCOM G6 TRANSMITTER$103
How this compares
$3,010 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $44,952 |
| JardianceEmpagliflozin | 31 | $31,269 |
| JanuviaSitagliptin Phosphate | 25 | $21,474 |
| OzempicSemaglutide | 18 | $16,534 |
| InvokanaCanagliflozin | 15 | $7,122 |
| MyrbetriqMirabegron | 14 | $6,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,905 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,431 |
| EdarbiAzilsartan Medoxomil | 11 | $2,514 |
| Pregabalin | 30 | $1,201 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 52 | $1,035 |
| Cholestyramine LightCholestyramine | 11 | $536 |
| Losartan Potassium | 36 | $523 |
| Levothyroxine Sodium | 77 | $512 |
| Olmesartan Medoxomil | 35 | $459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $219 | $44,95239 claims |
| Novo NordiskOzempic | $294 | $16,53418 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $27 | $2,51411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Pooler
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.